FOLD250117P7000
- 0.00
- 0.000.00%
Amicus Therapeutics Newsroom
Jefferies Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $18
Morgan Stanley Upgrades PTC, Cuts Immuneering, Amicus
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Amicus Therapeutics (FOLD) Is a Top-Ranked Momentum Stock: Should You Buy?
Amicus Therapeutics Cut to Equal-Weight From Overweight by Morgan Stanley
Morgan Stanley Downgrades Amicus Therapeutics(FOLD.US) to Hold Rating, Cuts Target Price to $12
Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Share Price Is Matching Sentiment Around Its Revenues
Insider Sale: President and CEO of $FOLD (FOLD) Sells 7,500 Shares
BioNJ Unveils "Time Off for Clinical Trials" Initiative
HALO Vs. FOLD: Which Stock Should Value Investors Buy Now?
Alkermes, DaVita, Jabil, Ralph Lauren, Among Potential M&A Candidates - BofA
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Announces Target Price $17
Amicus Therapeutics Price Target Raised to $17.00/Share From $16.00 by JP Morgan
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable?
J.P. Morgan Maintains Amicus Therapeutics(FOLD.US) With Buy Rating
A Quick Look at Today's Ratings for Amicus Therapeutics(FOLD.US), With a Forecast Between $15 to $21
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Amicus Therapeutics: Strong Financial Performance and Strategic Advancements Drive Buy Rating
Amicus Therapeutics Is Maintained at Buy by Guggenheim